Theravance Biopharma (NASDAQ:TBPH) Given “Neutral” Rating at B. Riley Financial

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “neutral” rating reaffirmed by equities researchers at B. Riley Financial in a research report issued on Wednesday,Benzinga reports. They currently have a $14.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $28.00. B. Riley Financial’s target price suggests a potential upside of 0.29% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. BTIG Research cut their price objective on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Oppenheimer initiated coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective for the company. HC Wainwright boosted their target price on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday. Finally, Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $13.96 on Wednesday. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The business’s fifty day moving average price is $19.26 and its two-hundred day moving average price is $16.88. The company has a market capitalization of $707.35 million, a P/E ratio of 24.49 and a beta of 0.17.

Institutional Trading of Theravance Biopharma

A number of large investors have recently added to or reduced their stakes in the business. Baader Bank Aktiengesellschaft acquired a new position in shares of Theravance Biopharma in the 3rd quarter worth $781,000. Hillsdale Investment Management Inc. acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at $4,536,000. Inspire Investing LLC purchased a new position in Theravance Biopharma in the 3rd quarter worth about $1,074,000. Assenagon Asset Management S.A. raised its holdings in Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after buying an additional 390,735 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in Theravance Biopharma by 76.8% during the 2nd quarter. Acadian Asset Management LLC now owns 308,652 shares of the biopharmaceutical company’s stock worth $3,401,000 after buying an additional 134,058 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Trending Headlines about Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: HC Wainwright raised its price target for TBPH to $27 and kept a buy stance, signaling at least one analyst sees upside if the company executes its strategic plan. HC Wainwright Raises Theravance Biopharma (NASDAQ:TBPH) Price Target to $27.00
• Positive Sentiment: Management highlighted a strong cash position (~$326.5M at Q4 2025; ~ $400M expected end-Q1 2026 including milestones), confidence in a $100M TRELEGY milestone, and a planned ~60% reduction in operating costs to preserve runway while focusing on YUPELRI (durable cash flow). These items support near-term liquidity and narrow the company’s focus. Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
• Neutral Sentiment: The board has accelerated a strategic review and engaged Lazard to evaluate alternatives (including a potential sale). Outcome is uncertain — could unlock value but also prolong distraction and execution risk. Theravance plans strategic review, including possible sale, after drug trial failure
• Neutral Sentiment: BTIG lowered its price target from $40 to $21 but maintained a Buy rating — that keeps institutional support visible, though the PT cut reflects the increased risk after the trial miss. Theravance Biopharma (TBPH) PT Lowered to $21 at BTIG following trial miss
• Negative Sentiment: The Phase 3 CYPRESS study of ampreloxetine in multiple system atrophy failed to meet the primary OHSA composite endpoint — the primary driver of the stock decline and the catalyst for the strategic review. Theravance Biopharma Plummets As Phase 3 Study Falls Short
• Negative Sentiment: Shares were halted and then plunged on the news; coverage notes the company may sell or be sold, creating near-term uncertainty and downside risk if buyers/valuations are weak. Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review
• Negative Sentiment: Unusually heavy put-option buying (roughly 6,696 puts traded — a ~983% increase vs. average) signals elevated bearish positioning and potential for continued downside pressure or volatility in the near term.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.